Home > Press > BioAlliance Pharma Takes Part in Paris MidCap Event September 17-18
BioAlliance Pharma SA (Euronext Paris - Code Isin: FR0010095596 -BIO), a specialty pharmaceutical company focused on the development and marketing of innovative therapeutics targeting cancer, HIV, opportunistic infections and drug resistance, announced today that it will take part in the MidCap Event, a forum dedicated to meetings between institutional investors and listed companies from the Euronext Zone, on September 17-18 in Paris.
BioAlliance Pharma Takes Part in Paris MidCap Event September 17-18
Paris, France | Posted on September 10th, 2007
Dominique Costantini, BioAlliance President and CEO, and Nicolas Fellmann, Chief Financial Officer, will meet institutional investors during one-on-one discussions to explain the company's accelerated growth strategy.
The MidCap Event is a forum dedicated to meetings between institutional investors and listed companies from the Euronext Zone.
About BioAlliance Pharma SA
BioAlliance Pharma SA (Euronext Paris: BIO) is a specialty pharmaceutical company focused on the development and commercialization of innovative therapeutics targeting cancer, HIV, opportunistic infections and drug resistance.
The company is currently conducting 3 phase III clinical trials on innovative products. Two products are based on the Lauriad(R) mucoadhesive technology, which allows an early and prolonged release of therapeutic agents at the site of the disease: one authorized product in France and two clinical international phase III trials ongoing (Loramyc(R) and acyclovir Lauriad(R)). One product is based on the Transdrug(R) nanoparticle technology designed specifically for intracellular targeting: one international phase III trial ongoing on primary liver cancer (doxorubicin Transdrug(R)). The company is also developing a New Entities program focused on new targets in oncology and HIV. The company concluded two strategic partnerships in 2007 to sell its Loramyc(R) product, recently launched on the French market, in Europe and in the US.
Disclaimer This communication expressly or implicitly contains certain forward-looking statements concerning BioAlliance Pharma SA and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of BioAlliance Pharma SA to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. BioAlliance Pharma SA is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of BioAlliance Pharma SA to differ from those contained in the forward-looking statements please refer to the Risk Factors (Facteurs de Risque) section of the reference document approved by the AMF on 6 April 2007 under the number R. 07-031, which is available on the AMF website www.amf-france.org or BioAlliance Pharma S.A.'s website http://www.bioalliancepharma.com
For more information, please click here
ANDREW LLOYD & ASSOCIATES
Brighton Business Centre
95 Ditchling Road Brighton
BN1 4ST ENGLAND
Tel: +44 1273 675100
Fax: +44 1273 675400
55 rue Boissonade
75014 Paris FRANCE
Tel: +33 1 56 54 07 00
Fax: +33 1 56 54 07 01
Copyright © BioAlliance Pharma SA
If you have a comment, please Contact
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Malaysian Nanotechnology Company Nanopac Innovation Ltd. lists on the NSX January 19th, 2015
Aspen Aerogels, Inc. to Present at the Needham Growth Conference January 8th, 2015
Blend Therapeutics Secures $21 Million Financing and Unveils Novel Pentarin™ Platform for Cancer Therapeutics: Company’s Technology and Expertise in Cancer R&D Evolve to Create New Class of Miniaturized Biologic Drug Conjugates (mBDCs) Encapsulated in Nanoparticles January 8th, 2015
Nanometrics to Announce Fourth Quarter and Full Year Financial Results on February 2, 2015 January 7th, 2015
Why Is Google Making Synthetic Arms? February 1st, 2015
DNA nanoswitches reveal how life's molecules connect: An accessible new way to study molecular interactions could lower cost and time associated with discovering new drugs January 30th, 2015
Made-in-Singapore rapid test kit detects dengue antibodies from saliva: IBN's MedTech innovation simplifies diagnosis of infectious diseases January 29th, 2015
Iranian Researchers Planning to Produce Edible Insulin January 28th, 2015
Why Is Google Making Synthetic Arms? February 1st, 2015
Nanomaterials Used to Reduce Heat Generated by LED Panels February 1st, 2015
Leader Describes Iran's Independence as Root Cause of Bullying Powers' Enmity February 1st, 2015
Performance Drop in Solar Cells Prevented by Nanotechnology February 1st, 2015
Hiden Gas Analysers at PITTCON 2015 | Visit us on Booth No. 1127 January 29th, 2015
Advantest to Exhibit at SEMICON Korea in Seoul, South Korea February 4-6 Showcasing Broad Portfolio of Semiconductor Products, Technologies and Solutions January 29th, 2015
Pittcon News: Renishaw adds to the comprehensive imaging options available with its inVia confocal Raman microscope January 27th, 2015
Nanometrics to Present at the Stifel 2015 Technology, Internet and Media Conference January 27th, 2015